➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
McKesson
Boehringer Ingelheim
Medtronic
Baxter

Last Updated: October 1, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,095,584

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,095,584 protect, and when does it expire?

Patent 9,095,584 protects GALAFOLD and is included in one NDA.

This patent has forty-nine patent family members in twenty-three countries.

Summary for Patent: 9,095,584
Title:Method to predict response to pharmacological chaperone treatment of diseases
Abstract: The present invention provides methods to determine whether a patient with a lysosomal storage disorder win benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining .alpha.-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of .alpha.-galactosidase A. The invention also provides a method for diagnosing Fabry disease in patients suspected of having Fabry disease.
Inventor(s): Benjamin; Elfrida (Millstone Township, NJ), Do; Hung V. (New Hope, NJ), Wu; Xiaoyang (Edison, NJ), Flanagan; John (East Windsor, NJ), Wustman; Brandon (San Diego, CA)
Assignee: AMICUS THERAPEUTICS, INC. (Cranbury, NJ)
Application Number:14/054,369
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 9,095,584

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Amicus Theraps Us GALAFOLD migalastat hydrochloride CAPSULE;ORAL 208623-001 Aug 10, 2018 RX Yes Yes   Start Trial   Start Trial THE TREATMENT OF FABRY PATIENTS   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,095,584

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 111971   Start Trial
Australia 2009214648   Start Trial
Australia 2014221321   Start Trial
Australia 2016206297   Start Trial
Australia 2017268649   Start Trial
Australia 2018220047   Start Trial
Australia 2018277756   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Medtronic
Colorcon
Dow
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.